Quantitative MRI Assessment of Pancreatic Steatosis Using Proton Density Fat Fraction in Pediatric Obesity

Jisoo Kim¹, Salman S. Albakheet¹, ², Kyunghwa Han¹, Haesung Yoon¹, ³, Mi-Jung Lee¹, ³, Hong Koh¹, ⁴, Seung Kim³, ⁴, Junghwan Suh⁵, Seok Joo Han³, ⁶, Kyong Ihn³, ⁶, Hyun Joo Shin¹, ³, ⁷

¹Department of Radiology, Severance Hospital, Research Institute of Radiological Science, Yonsei University College of Medicine, Seoul, Korea; ²Department of Radiology, King Faisal General Hospital, Al-Hofuf, Saudi Arabia; ³Severance Pediatric Liver Disease Research Group, Severance Children’s Hospital, Yonsei University College of Medicine, Seoul, Korea; Departments of ⁴Pediatric Gastroenterology, Hepatology and Nutrition, ⁵Pediatric Endocrinology, and ⁶Pediatric Surgery, Severance Children’s Hospital, Yonsei University College of Medicine, Seoul, Korea; ⁷Department of Radiology, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Korea

Objective: To assess the feasibility of quantitatively assessing pancreatic steatosis using magnetic resonance imaging (MRI) and its correlation with obesity and metabolic risk factors in pediatric patients.

Materials and Methods: Pediatric patients (≤ 18 years) who underwent liver fat quantification MRI between January 2016 and June 2019 were retrospectively included and divided into the obesity and control groups. Pancreatic proton density fat fraction (P-PDFF) was measured as the average value for three circular regions of interest (ROIs) drawn in the pancreatic head, body, and tail. Age, weight, laboratory results, and mean liver MRI values including liver PDFF (L-PDFF), stiffness on MR elastography, and T2* values were assessed for their correlation with P-PDFF using linear regression analysis. The associations between P-PDFF and metabolic risk factors, including obesity, hypertension, diabetes mellitus (DM), and dyslipidemia, were assessed using logistic regression analysis.

Results: A total of 172 patients (male:female = 125:47; mean ± standard deviation [SD], 13.2 ± 3.1 years) were included. The mean P-PDFF was significantly higher in the obesity group than in the control group (mean ± SD, 4.2 ± 2.5% vs. 3.4 ± 2.4%; p = 0.037). L-PDFF and liver stiffness values showed no significant correlation with P-PDFF (p = 0.235 and p = 0.567, respectively). P-PDFF was significantly associated with obesity (odds ratio 1.146, 95% confidence interval 1.006–1.307, p = 0.041), but there was no significant association with hypertension, DM, and dyslipidemia.

Conclusion: MRI can be used to quantitatively measure pancreatic steatosis in children. P-PDFF is significantly associated with obesity in pediatric patients.

Keywords: Child; Pancreas; Fatty liver; Magnetic resonance imaging; Obesity

INTRODUCTION

Non-alcoholic fatty liver disease (NAFLD) is a metabolic disease characterized by the accumulation of ectopic fat in the liver that can lead to liver cirrhosis and hepatocellular carcinoma without appropriate intervention [1]. Similar to NAFLD, non-alcoholic fatty pancreas disease (NAFPD) is characterized by fat infiltration and has recently emerged as a new metabolic disease [2-4]. Recently, several studies have been conducted on NAFPD, and pancreatic fat infiltration has been found to affect pancreatic insulin secretion and potentially act as a risk factor for pancreatic cancer, chronic pancreatitis, and diabetes mellitus (DM) in adults [5-7]. Although there have not been several studies on adults with liver disease or even NAFLD, recent studies have shown that pediatric NAFPD is not uncommon in children, and it can affect glucose metabolism, islet cell dysfunction, and liver fibrosis associated with pediatric NAFLD [2,8].

Pancreatic fat can be evaluated using ultrasonography (US), computed tomography (CT), magnetic resonance...
imaging (MRI), and magnetic resonance spectroscopy (MRS) [9-11]. However, the US has some disadvantages because it is difficult to identify the full length of the pancreas with a poor sonographic window, such as those used in obese patients, and because it is also relatively subjective because fat infiltration is measured qualitatively [12,13]. In contrast, CT and MRI can evaluate the entire pancreas, regardless of patient factors, and measure the amount of fat. Several previous studies have shown that their performance is comparable when measuring hepatic fat, even though studies have yet to directly compare their pancreatic fat measurements [13,14].

Among the various MRI-based methods for fat quantification, proton density fat fraction (PDFF) is considered the most practical and objective because the fat fraction can be obtained quantitatively by separating water and fat using a chemical shift technique [15]. In addition, MRI may seem more advantageous for pediatric patients because it allows patients to avoid radiation issues that can occur with CT. However, there are still not enough studies on factors related to pancreatic fat accumulation in pediatric patients. According to a previous study, pancreatic fat measured with MRS was significantly higher in obese children and not significantly related to prediabetes [16]. Two other studies evaluated fatty pancreas with US and found that insulin resistance was higher in pediatric patients with, than in those without, fatty pancreas [2]. However, there have been very few analyses of pancreatic fat using PDFF in pediatric patients.

Therefore, this study aimed to quantitatively measure pancreatic fat deposition using PDFF values of MRI and evaluate its correlation with obesity and metabolic risk factors in children.

MATERIALS AND METHODS

Subjects

This retrospective study was approved by the Institutional Review Board of our institution, and the requirement for informed consent was waived (IRB No. 4-2020-0470). Pediatric patients (≤ 18 years) who underwent abbreviated liver MRI containing the PDFF sequence according to clinical demands between January 2016 and June 2019 were consecutively included. We included patients who underwent abbreviated liver MRI because they were suspected to have NAFLD due to elevated liver enzymes, obesity, or abnormal hyperechogenicity of the liver parenchyma on US. In patients who underwent repeated liver MRI, we only included results from the initial examination before the patients were treated for the disease. We excluded patients with laboratory results obtained more than 1 month before and after the MRI examinations. We excluded patients who underwent MRI because of a suspicion of liver fibrosis due to other causes, such as biliary atresia.

After reviewing the medical records of the entire population, the age, weight, height, and presence of metabolic risk factors, such as hypertension, DM, and dyslipidemia, were reviewed. Hypertension, DM, and dyslipidemia were diagnosed by pediatric endocrinologists according to previous studies and guidelines [17-19]. The laboratory results were reviewed for the serum levels of aspartate aminotransferase (AST, IU/L), alanine transaminase (ALT, IU/L), γ-glutamyl transferase (GGT, IU/L), fasting glucose (mg/dL), total cholesterol (mg/dL), triglycerides (mg/dL), high-density lipoprotein cholesterol (HDL, mg/dL), low-density lipoprotein cholesterol (LDL, mg/dL), amylase (U/L), and lipase (U/L). The patients were divided into two groups: the control and obesity groups. The obesity group was defined as having a body mass index (BMI) falling within the 95th percentile or above.

MRI Acquisition

All abbreviated liver MRIs were performed using a 3T system (Discovery MR750w; GE Healthcare) with a pediatric body coil. Patients who could cooperate with image acquisition and breath-holding could undergo MRI because sedation was not supported in this MRI system at our institution. For MRI, axial single-shot fast-spin-echo T2 weighted images were included for anatomic imaging of the liver. The three-dimensional volumetric multi-echo gradient echo sequence (IDEAL-IQ) sequence was used to obtain PDFF and T2* (= 1/R2*) values, using the following parameters: repetition time (TR), 5.9 ms; echo time (TE), 2.6 ms; field of view, 42 cm; matrix, 128 x 128; flip angle, 3°; slice thickness, 8.0 mm; and acquisition time, 16 seconds. The fat and R2* maps were generated automatically after acquisition. In addition, the MR elastography (MRE) sequence was included using a passive driver placed over the right anterior abdominal wall to deliver 60-Hz pneumatic vibrations. The two-dimensional spin-echo echo-planar imaging (SE-EPI) sequence was used to obtain four axial stiffness maps of the liver using the following parameters: TR, 1000 ms; TE, 62 ms; field of view, 38 cm; matrix, 64 x 64; flip angle, 90°; slice thickness, 8.0 mm;
and acquisition time, 24 seconds. The MRE acquisition technique was the same as that used in previous pediatric studies [20,21].

**MRI Analysis**

To obtain pancreatic PDFF (P-PDFF, %), a radiologist with six months of experience in pediatric radiology drew circular regions of interest (ROIs) on the pancreas using a picture archiving and communication system (PACS, Centricity, General Electric Corporation). A total of three round ROIs with an approximate area of 100 mm² were drawn over the pancreas head, body, and tail portions on the fat map according to previous studies (Figs. 1, 2) [9,22]. The average P-PDFF value calculated from the three fat fractions in the pancreas was used as the representative value. An average pancreas T2* value was also obtained using the three-round ROIs drawn on the R2* map in the pancreas head, body, and tail. The liver PDFF (L-PDFF, %) and T2* values were acquired from the three circular ROIs in the liver from the fat and R2* maps while avoiding hepatic vessels.

To obtain liver stiffness values, the circular ROIs were drawn on each of the four axial liver stiffness maps with 95% confidence intervals (CIs), while avoiding artifacts and vessels. The mean liver stiffness value for the four ROIs (one from each axial stiffness map) was used as the representative value. The ROIs used were different from those of the fat map because the stiffness map was obtained for four axial slices of different slice thicknesses from the fat map, and copying ROIs to the same areas was not possible with our PACS. All measurements were obtained by radiologists blinded to the clinical information.

**Statistical Analysis**

The statistical analyses were performed using SPSS version 25 (IBM Corp.). Continuous variables were expressed as mean ± standard deviation (SD), and categorical variables were summarized as frequencies and percentages. To determine the reliability of the P-PDFF measurements, another pediatric radiologist with seven years of experience in pediatric radiology drew round ROIs on the pancreas head, body, and tail on the fat map while blinded to previous measurements and patient history. The mean P-PDFF values were calculated from the three ROIs. To assess the intraobserver variability for the P-PDFF measurements, the same pediatric radiologist drew three ROIs on the pancreas head, body, and tail on the fat map two weeks later, while blinded to the previous measurements and patient history. The intraclass correlation coefficient (ICC) values were calculated to evaluate interobserver and intraobserver variability for the P-PDFF.

---

**Fig. 1.** A 10-year-old obese boy showed (A) increased liver-PDFF (33%) and (B) increased liver stiffness (3.2 kPa). (C) His mean pancreatic-PDFF value was 7.2%. PDFF = proton density fat fraction

**Fig. 2.** A 16-year-old non-obese boy showed (A) increased liver-PDFF (34%) and (B) normal range of liver stiffness (1.7 kPa). (C) His mean pancreatic-PDFF value was 1.9%. The pancreatic-PDFF was not increased in this patient with a normal range of liver stiffness. PDFF = proton density fat fraction
MRI Assessment of Pancreatic Steatosis in Children

measurements. The ICC values were interpreted as follows: < 0.5, poor reliability; 0.5 and 0.75, moderate reliability; 0.75 and 0.9, good reliability; and values greater than 0.9, excellent reliability.

We compared the continuous variables for the control and obesity groups using an independent t test. The chi-squared and Fisher’s exact tests were used to compare the categorical variables. Univariable linear regression analysis was used to find associations between P-PDFF and metabolic risk factors, such as obesity, hypertension, DM, and dyslipidemia. Statistical significance was set at \( p < 0.05 \).

RESULTS

Patient Demographics

All 264 patients underwent abbreviated liver MRI containing the PDFF sequence during the study period. Among them, 54 patients were excluded because they did not have laboratory results within 1 month of the MRI examination. In addition, 38 patients were excluded because they underwent MRI to evaluate liver fibrosis, such as biliary atresia. Therefore, a total of 172 pediatric patients (male:female = 125:47; mean ± SD, 13.2 ± 3.1 years; range 7–18 years) were included. Among them, 138 patients were consequently diagnosed with NAFLD after liver MRI using a cutoff value of 6% for the L-PDFF [23]. The remaining 34 patients did not have NAFLD despite undergoing MRI because of suspicions of increased liver parenchymal echogenicity on abdominal US. Eighty-eight patients were classified into the obesity group with a BMI falling within the 95% percentile or higher (51.2%; mean ± SD, 13.6 ± 3.1 years; range 7–18 years). Ten patients had hypertension (5.8%), 21 had DM (12.2%), and 8 had dyslipidemia (4.7%). All the DM cases were type 2.

P-PDFF Value and Its Reliability on Measurement

The mean P-PDFF ± SD of all patients was 3.8 ± 2.5%. The ICC value of the interobserver variability for the P-PDFF measurement was 0.798, indicating a good agreement. The ICC value for intraobserver variability was 0.924, indicating excellent reliability.

Comparison of the Control and Obesity Group

AST (mean ± SD, 91.2 ± 151.6 IU/L vs. 44 ± 43.4 IU/L, \( p = 0.006 \)) and ALT (mean ± SD, 160.7 ± 215.0 IU/L vs. 73.2 ± 102.0 IU/L, \( p = 0.001 \)) were significantly higher in the obesity group. HDL levels were significantly lower in the obesity group than in the control group (mean ± SD, 44.3 ± 10.9 mg/dL vs. 49.1 ± 13.7 mg/dL, \( p = 0.025 \)).

When comparing MRI results, P-PDFF was significantly higher in the obesity group (mean ± SD, 4.2 ± 2.5% vs. 3.4 ± 2.4%, \( p = 0.037 \)). The T2* values of the pancreas could not be measured in six patients due to artifacts. In these patients, the unmeasurable area, including the pancreas, appeared as a black signal intensity from motion artifacts or air in the stomach. Based on the pancreas T2* values available in 166 patients, there was no significant difference between the two groups (\( p = 0.503 \)). L-PDFF was significantly higher in the obesity group (mean ± SD, 24.7 ± 13.4% vs. 16.5 ± 14.1%, \( p < 0.001 \)). Liver T2* values and stiffness values were not significantly different between the two groups (\( p = 0.957 \) and \( p = 0.125 \), respectively).

DM was more frequently observed in the obesity group than in the control group (15 vs. 6 patients, \( p = 0.047 \)), while the incidence of hypertension and dyslipidemia were not significantly different. The clinical, laboratory, and MRI results are shown in Table 1.

Factors associated with Pancreatic Fat Fraction and Its Relationship with Metabolic Risk Factors

In the univariable linear regression analysis, only amylase was significantly associated with P-PDFF (\( \beta = -0.034, p = 0.022 \)) (Table 2). Other MRI values, including pancreas T2* values, L-PDFF, and liver stiffness, showed no significant association with P-PDFF in the linear regression analysis. Among the metabolic risk factors, P-PDFF was associated with obesity (odds ratio [OR] 1.146, 95% CI 1.006–1.307, \( p = 0.041 \)) in the univariable logistic regression analysis. There were no significant associations between P-PDFF and hypertension (OR 1.019, 95% CI 0.791–1.312, \( p = 0.885 \)), DM (OR 1.035, 95% CI 0.866–1.236, \( p = 0.705 \)) and dyslipidemia (OR 0.946; 95% CI 0.689–1.298, \( p = 0.730 \)) (Table 3).

DISCUSSION

In this study, P-PDFF was significantly associated with obesity in pediatric patients (OR 1.193; 95% CI 1.057–1.348). In obese patients, P-PDFF was 4.2%, compared to 3.4% in the control group. Although P-PDFF was not
significantly associated with L-PDFF or liver stiffness values in our study cohort, this study demonstrated the usefulness of MRI for the quantification of pancreatic fat in pediatric populations with good to excellent reliability. The importance of pancreatic steatosis has been less investigated than that of NAFLD. However, pancreatic steatosis, also called NAFPD, has recently emerged as an important early marker of metabolic syndrome in adults. A previous study mentioned that NAFPD may play a role in the future development of DM, metabolic syndrome, atherosclerosis, and even pancreatic cancer in adults [3]. However, quantifying pancreatic fat with pathology is almost impossible, and this may be the reason for the late research on NAFPD. Therefore, noninvasive and quantitative measurement of P-PDFF may demonstrate the clinical importance of NAFPD in the metabolic disease of adults and, especially, children.

In adults, increased fatty infiltration is observed in the pancreas of obese patients on MRI [3,24]. However, a few studies have dealt with fatty pancreas in children and have tried to quantify pancreatic fat using MRI. Most of these studies assessed the degree of fatty pancreas using US [8,25]. Elhady et al. [8] demonstrated that obesity is associated with higher pancreatic fat on US in children, which is consistent with the results of our study. They diagnosed fatty pancreas when the pancreas showed similar or higher echogenicity compared to the renal sinus fat on US. However, this is not a quantitative measurement. As an alternative method for quantifying the degree of

| Characteristics | Control Group (n = 84) | Obesity Group (n = 88) | P |
|-----------------|------------------------|----------------------|---|
| Age, years      | 12.8 ± 3.0             | 13.6 ± 3.1           | 0.056 |
| Sex, male:female* | 60:24                  | 65:23                | 0.720 |
| Height, cm      | 153.1 ± 14.8           | 162.9 ± 13.3         | < 0.001 |
| Weight, kg      | 53.2 ± 14.8            | 82.0 ± 20.3          | < 0.001 |
| BMI percentage, %| 72.5 ± 26.3            | 98.5 ± 13.1          | < 0.001 |
| AST, IU/L       | 44.0 ± 43.4            | 91.2 ± 151.6         | 0.006 |
| ALT, IU/L       | 73.2 ± 102.0           | 160.7 ± 215.0        | 0.001 |
| γGT, IU/L       | 56.9 ± 29.0            | 66.3 ± 51.9          | 0.555 |
| Fasting glucose, mg/dL | 98.6 ± 34.8 | 101.8 ± 31.0         | 0.531 |
| Total cholesterol, mg/dL | 185.8 ± 45.9 | 187.8 ± 72.5         | 0.830 |
| Triglyceride, mg/dL | 137.3 ± 87.3          | 152.6 ± 80.4         | 0.282 |
| HDL, mg/dL      | 49.1 ± 13.7            | 44.3 ± 10.9          | 0.025 |
| LDL, mg/dL      | 130.8 ± 63.0           | 137.9 ± 123.5        | 0.835 |
| Amylase, U/L    | 66.8 ± 31.5            | 52.4 ± 16.9          | 0.098 |
| Lipase, U/L     | 26.5 ± 10.7            | 26.7 ± 8.5           | 0.951 |
| P-PDFF, %       | 3.4 ± 2.4              | 4.2 ± 2.5            | 0.037 |
| Pancreas T2*, msec | 33.6 ± 8.0            | 32.8 ± 7.6           | 0.503 |
| L-PDFF, %       | 16.5 ± 14.1            | 24.7 ± 13.4          | < 0.001 |
| Liver T2*, msec | 20.5 ± 5.3             | 20.4 ± 6.6           | 0.957 |
| Liver stiffness, kPa | 2.4 ± 0.7             | 2.6 ± 0.6            | 0.125 |
| Hypertension*   | 4 (4.8)                | 6 (6.8)              | 0.747 |
| Diabetes mellitus* | 6 (7.1)               | 15 (17)              | 0.047 |
| Dyslipidemia*   | 4 (4.8)                | 4 (4.5)              | > 0.999 |

Values are presented as mean ± SD or numbers or patient number with percentage in parentheses. *Chi-square test or Fisher’s exact test was used. ALT = alanine transaminase, AST = aspartate aminotransferase, BMI = body mass index, HDL = high-density lipoprotein cholesterol, L = liver, LDL = low-density lipoprotein cholesterol, P = pancreatic, PDFF = proton density fat fraction, SD = standard deviation, γGT = γ-glutamyl transferase
In this study, the mean P-PDFF of the control group was 3.4% ± 2.4%. Although the normal standard for pancreatic fat fraction has not yet been clearly determined, the average pancreatic fat fraction in a healthy population was 4.5% ± 0.9% in a meta-analysis of nine MRI studies [31]. However, as fat deposition increases with age, adults and children may have different normal values [32]. Thus, this standard in adults cannot be applied equally to children, even though two studies with pediatric subjects were included in this meta-analysis. One study that evaluated P-PDFF using the Dixon method divided children into three groups: lean without metabolic syndrome, obese without metabolic syndrome, and obese with metabolic syndrome, where the pancreatic fat fraction was 3.6 ± 0.9%, 4.7 ± 1.1%, and 5.3 ± 1.5%, respectively [33]. The mean P-PDFF of the control group in our study was also lower than that in the adults. Because the control group in our study was determined by the BMI percentage only, the included subjects may differ from previous studies and may not fully represent healthy controls. For example, the mean L-PDFF in the control group was 16.5%. This value was above the cutoff known to represent fat deposition in the liver of children [23]. Therefore, even though we divided groups according to BMI percentage, the control group did not represent healthy normal children. However, because quantifying pancreatic fat using histologic confirmation is realistically impossible in children, we need to validate the normal fat signal percentage using MRI with a large number of subjects for future and deeper analyses of pediatric NAFLD.

In addition, P-PDFF was significantly higher in the obesity group than in the control group. Although L-PDFF and liver stiffness were not significantly associated with P-PDFF in our study, there is still not enough data on the relationship between liver fibrosis and fat infiltration in the pancreas. Previous studies have demonstrated that patients with fatty pancreas have more advanced NAFLD than patients without fatty pancreas [2,29]. However, one study reported a positive correlation between fatty liver and fatty pancreas, but a negative correlation between liver fibrosis and fatty pancreas [34]. This finding suggests that further research is required.

This retrospective study had several limitations. First, this study analyzed the fat fraction measured indirectly by MRI and not the histological fat fraction obtained through biopsy or surgery on the liver and pancreas. As we mentioned earlier, because of the retrospective nature of this study, the control group did not represent healthy and normal children. However, obtaining histological confirmation has many limitations. For the same reason, previous studies have shown that PDFF can accurately predict fat percentage, with a reasonable agreement between histological measurements and P-PDFF [35,36]. Second, the number of patients with metabolic risk factors was relatively low. This is because we included patients who underwent liver MRI due to the suspicion of liver disease and not metabolic disease. In addition, because metabolic syndrome, DM, and pancreatitis are chronic diseases, long-term follow-up is necessary for more accurate assessments. Future studies incorporating a long-term follow-up will provide a more accurate picture of the associations between P-PDFF and chronic diseases in pediatric patients.

In conclusion, pancreatic steatosis can be measured quantitatively using MRI in pediatric patients with good to excellent reliability. P-PDFF is significantly associated with...
obesity in pediatric patients. Further studies are needed to assess the clinical implications of pediatric NAFPD using MRI.

Conflicts of Interest
The authors have no potential conflicts of interest to disclose.

Author Contributions
Conceptualization: Hyun Joo Shin. Data curation: Salman S. Albakheet, Jisoo Kim, Hyun Joo Shin. Formal analysis: Hyun Joo Shin, Kyunghwa Han. Resources: Hong Koh, Seung Kim, Seok Joo Han, Kyong Ihn, Junghwan Suh. Software: Hyun Joo Shin, Haesung Yoon, Mi-Jung Lee. Supervision: Hyun Joo Shin. Validation: Jisoo Kim, Hyun Joo Shin. Writing—original draft: Jisoo Kim, Hyun Joo Shin. Writing—review & editing: Hyun Joo Shin, Jisoo Kim, Mi-Jung Lee, Haesung Yoon.

ORCID iDs
Jisoo Kim
https://orcid.org/0000-0002-3481-127X
Salman S. Albakheet
https://orcid.org/0000-0001-5998-0355
Kyunghwa Han
https://orcid.org/0000-0002-5687-7237
Haesung Yoon
https://orcid.org/0000-0003-0581-8656
Mi-Jung Lee
https://orcid.org/0000-0003-3244-9171
Hong Koh
https://orcid.org/0000-0002-3660-7483
Seung Kim
https://orcid.org/0000-0003-4373-9828
Junghwan Suh
https://orcid.org/0000-0002-2092-2585
Seok Joo Han
https://orcid.org/0000-0001-5224-1437
Kyong Ihn
https://orcid.org/0000-0002-6161-0078
Hyun Joo Shin
https://orcid.org/0000-0002-7462-2609

REFERENCES

1. Kanwal F, Kramer JR, Mapakshi S, Natarajan Y, Chayanupatkul M, Richardson PA, et al. Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease. *Gastroenterology* 2018;155:1828-1837.e2
2. Della Corte C, Mosca A, Majo F, Lucidi V, Panera N, Giglioni E, et al. Nonalcoholic fatty pancreas disease and nonalcoholic fatty liver disease: more than ectopic fat. *Clin Endocrinol (Oxf)* 2015;83:656-662
3. Catanzano R, Cuffari B, Italia A, Marotta F. Exploring the metabolic syndrome: nonalcoholic fatty pancreas disease. *World J Gastroenterol* 2016;22:7660-7675
4. Lesmana CR, Pakasi LS, Ingrigiani S, Aidawati ML, Lesmana LA. Prevalence of non-alcoholic fatty pancreas disease (NAFPD) and its risk factors among adult medical check-up patients in a private hospital: a large cross sectional study. *BMC Gastroenterol* 2015;15:174
5. Fujii M, Ohno Y, Yamada M, Kamada Y, Miyoshi E. Impact of fatty pancreas and lifestyle on the development of subclinical chronic pancreatitis in healthy people undergoing a medical checkup. *Environ Health Prev Med* 2019;24:10
6. Fukuda Y, Yamada D, Eguchi H, Hata T, Iwagami Y, Noda T, et al. CT density in the pancreas is a promising imaging predictor for pancreatic ductal adenocarcinoma. *Ann Surg Oncol* 2017;24:2762-2769
7. Heni M, Machann J, Staiger H, Schwener NF, Peter A, Schick F, et al. Pancreatic fat is negatively associated with insulin secretion in individuals with impaired fasting glucose and/or impaired glucose tolerance: a nuclear magnetic resonance study. *Diabetes Metab Res Rev* 2010;26:200-205
8. Elhady M, Elazab AAAM, Bahagat KA, Abdallah NA, Ibrahim GE. Fatty pancreas in relation to insulin resistance and metabolic syndrome in children with obesity. *J Pediatr Endocrinol Metab* 2019;32:19-26
9. Ilidilman IS, Tuzun A, Savas B, Elhan AH, Celik A, Ilidilman R, et al. Quantification of liver, pancreas, kidney, and vertebral body MRI-PDFF in non-alcoholic fatty liver disease. *Abdom Imaging* 2015;40:1512-1519
10. Kim SY, Kim H, Cho JY, Lim S, Cha K, Lee KH, et al. Quantitative assessment of pancreatic fat by using unenhanced CT: pathologic correlation and clinical implications. *Radiology* 2014;271:104-112
11. Lesmana CRA, Gani RA, Lesmana LA. Non-alcoholic fatty pancreas disease as a risk factor for pancreatic cancer based on endoscopic ultrasound examination among pancreatic cancer patients: a single-center experience. *JGH Open* 2018;2:4-7
12. Shmulewitz A, Teefey SA, Robinson BS. Factors affecting image quality and diagnostic efficacy in abdominal sonography: a prospective study of 140 patients. *J Clin Ultrasound* 1993;21:623-630
13. Kramer H, Pickhardt PJ, Kliwer MA, Hernando D, Chen GH, Zagzebski JA, et al. Accuracy of liver fat quantification with
advanced CT, MRI, and ultrasound techniques: prospective comparison with MR spectroscopy. AJR Am J Roentgenol 2017;208:92-100
14. Maruzzelli L, Parr AJ, Miraglia R, Tuzzolino F, Luca A. Quantification of hepatic steatosis: a comparison of computed tomography and magnetic resonance indices in candidates for living liver donation. Acad Radiol 2014;21:507-513
15. Reeder SB, Hu HH, Sirlin CB. Proton density fat-fraction: a standardized MR-based biomarker of tissue fat concentration. J Magn Reson Imaging 2012;36:1011-1014
16. Pacifico L, Di Martino M, Anania C, Andreoli GM, Beazzi M, Catalano C, et al. Pancreatic fat and β-cell function in overweight/obese children with nonalcoholic fatty liver disease. World J Gastroenterol 2015;21:4688-4695
17. Kim SH, Park Y, Song YH, An HS, Shin JI, Oh JH, et al. Blood pressure reference values for normal weight Korean children and adolescents: data from the Korea National Health and Nutrition Examination Survey 1998–2016: the Korean Working Group of Pediatric Hypertension. Korean Circ J 2019;49:1167-1180
18. Lim JS, Kim EY, Kim JH, Yoo JH, Yi KH, Chae HW, et al. 2017 Clinical practice guidelines for dyslipidemia of Korean children and adolescents. Ann Pediatr Endocrinol Metab 2020;25:199-207
19. Zeitler P, Arslanian S, Fu J, Pinhas-Hamiel O, Reinehr T, Tandon N, et al. ISPAD Clinical Practice Consensus Guidelines 2018: type 2 diabetes mellitus in youth. Pediatr Diabetes 2018;19 Suppl 27:28-46
20. Binkovitz LA, El-Youssef M, Glaser KJ, Yin M, Binkovitz AK, Ehman RL. Pediatric MR elastography of hepatic fibrosis: principles, technique and early clinical experience. Pediatr Radiol 2012;42:402-409
21. Serai SD, Towbin AJ, Podberesky DJ. Pediatric liver MR elastography. Dig Dis Sci 2012;57:2713-2719
22. Hui SCN, Wong SKH, Ai Q, Yeung DKW, Ng EKW, Chu WCW. Observed changes in brown, white, hepatic and pancreatic fat after bariatric surgery: evaluation with MRI. Eur Radiol 2019;29:845-856
23. Shin HJ, Kim HG, Kim MJ, Koh H, Kim HY, Roh YH, et al. Normal range of hepatic fat fraction on dual- and triple-echo fat quantification MR in children. PLoS One 2015;10:e0117480
24. Pinte L, Balaban DV, Báicuț C, Jinga M. Non-alcoholic fatty pancreas disease-practices for clinicians. Rom J Intern Med 2019;57:209-219
25. Kim DR, Lee MS, Lee JS, Choi GM, Kang KS. Ultrasonographic quantitative analysis of fatty pancreas in obese children: its correlation with metabolic syndrome and homeostasis model assessment of insulin resistance. J Pediatr 2018;193:134-138. e1
26. Jeong HT, Lee MS, Kim MJ. Quantitative analysis of pancreatic echogenicity on transabdominal sonography: correlations with metabolic syndrome. J Clin Ultrasound 2015;43:98-108
27. Regnell SE, Peterson P, Trinh L, Broberg P, Leemmark Å, et al. Pancreas volume and fat fraction in children with Type 1 diabetes. Diabet Med 2016;33:1374-1379
28. Smits MM, van Geenen EJ. The clinical significance of pancreatic steatosis. Nat Rev Gastroenterol Hepatol 2011;8:169-177
29. Guglielmi V, Sbraccia P. Type 2 diabetes: does pancreatic fat really matter? Diabetes Metab Res Rev 2018;34:e2955
30. Yamazaki H, Tsuboya T, Katanuma A, Kodama Y, Tsuchi S, Dohke M, et al. Lack of independent association between fatty pancreas and incidence of type 2 diabetes: 5-year Japanese cohort study. Diabetes Care 2016;39:1677-1683
31. Singh RG, Yoon HD, Wu LM, Lu J, Plank LD, Petrov MS. Ectopic fat accumulation in the pancreas and its clinical relevance: a systematic review, meta-analysis, and meta-regression. Metabolism 2017;69:1-13
32. Olsen TS. Lipomatosis of the pancreas in autopsy material and its relation to age and overweight. Acta Pathol Microbiol Scand A 1978;86:367-373
33. Maggio AB, Mueller P, Wacker J, Viallon M, Belli DC, Beghetti M, et al. Increased pancreatic fat fraction is present in obese adolescents with metabolic syndrome. J Pediatr Gastroenterol Nutr 2012;54:720-726
34. Patel NS, Peterson MR, Brenner DA, Heba E, Sirlin C, Loomba R. Association between novel MRI-estimated pancreatic fat and liver histology-determined steatosis and fibrosis in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2013;37:630-639
35. Klopfenstein BJ, Kim MS, Krisky CM, Szumowski J, Rooney WD, Purnell JQ. Comparison of 3 T MRI and CT for the measurement of visceral and subcutaneous adipose tissue in humans. Br J Radiol 2012;85:e826-e830
36. Yoon JH, Lee JM, Lee KB, Kim SW, Kang MJ, Jang JY, et al. Pancreatic steatosis and fibrosis: quantitative assessment with preoperative multiparametric MR imaging. Radiology 2016;279:140-150